b
r
c
inhal
bacteri
sialidas
function
remov
sialic
acid
sia
surfac
epitheli
cell
prevent
attach
subsequ
infect
respiratori
virus
util
sia
receptor
typic
bacteri
sialidas
cleav
sia
sia
linkag
also
demonstr
effect
acetyl
hydroxyl
form
sia
potenc
compound
enhanc
coupl
activ
sialidas
amphiregulin
tag
allow
longer
durat
action
minim
spread
system
circul
phase
ii
develop
treatment
influenza
also
demonstr
activ
individu
case
parainfluenza
immunosuppress
patient
continu
evalu
role
activ
bacteri
sialidas
requir
expand
rang
success
antivir
therapi
target
sia
deriv
interact
involv
viral
polypeptid
attach
protein
cognat
cellsurfac
receptor
first
antivir
compound
phase
ii
develop
function
block
pathogenhost
interact
destroy
influenza
hostcel
receptor
sialic
acid
sia
surfac
respiratori
epitheli
cell
paper
provid
background
inform
sia
sialidas
discuss
potenti
role
bacteri
sialidas
antivir
agent
review
vitro
phase
ii
evalu
treatment
influenza
note
evid
drug
would
also
use
parainfluenza
viru
infect
current
antivir
strategi
focu
prevent
viral
replic
within
cell
inhibit
releas
newli
form
virion
neuraminidas
na
inhibitor
primarili
act
step
play
minor
role
modul
viral
entri
matrosovich
et
al
first
step
viral
bind
often
involv
close
contact
viral
attach
protein
host
receptor
develop
studi
demonstr
natur
compound
present
serum
particular
alpha
inhibit
viru
adsorpt
surfac
hanaoka
et
al
later
studi
identifi
sia
key
determin
bind
compound
pritchett
et
al
pritchett
paulson
lentz
propos
number
strategi
prevent
cell
entri
block
host
receptor
lentz
lentz
mainli
direct
develop
antibodymedi
approach
rather
receptor
destruct
wei
colleagu
use
xray
crystallographi
map
haemagglutininsia
interact
wei
et
al
structur
solv
envis
might
possibl
develop
synthet
analog
sia
block
bind
pritchett
et
al
pritchett
paulson
though
acknowledg
drug
design
would
number
structur
obstacl
wei
et
al
rout
antiinfluenza
therapi
pursu
much
detail
block
viral
neuraminidas
site
two
recent
report
develop
drug
design
block
ha
bind
site
use
databas
commerci
avail
compound
zinc
nandi
techniqu
alqattan
mordi
b
blessia
et
al
springer
ansel
found
influenza
virus
bacteria
common
enzym
properti
abil
remov
receptor
red
blood
cell
prevent
haemagglutin
springer
ansel
investig
requir
understand
natur
sia
presenc
respiratori
tract
structur
function
bacteri
sialidas
sialic
acid
term
use
famili
ninecarbon
monoscaccharid
found
anim
certain
bacteria
chen
varki
typic
found
termin
portion
oligosaccharid
chain
attach
protein
lipid
form
glycoprotein
glycolipid
respect
natur
occur
variant
ninecarbon
ketosugar
base
neuramin
acid
neu
acid
kdn
backbon
schauer
varki
discoveri
neuramin
acid
klenk
colleagu
review
schaeur
schauer
term
sialic
acid
propos
blix
gottschalk
klenk
base
greek
word
sialion
salivea
carbohydr
isol
mucin
submaxillari
gland
sialic
acid
structur
function
sialic
acid
structur
divers
sia
present
natur
due
substitut
carbon
oacetyl
sulfat
methyl
lactat
group
glycosid
linkag
anomer
c
hydroxyl
group
galactos
gal
refer
nacetyl
galactosamin
galnac
nacetyl
glucosamin
glcnac
varki
varki
fig
eleven
differ
type
sialic
acid
identifi
human
erythrocyt
membran
use
ga
chromatographi
mass
spectrometri
bulai
et
al
galnac
typic
present
oglycan
glcnac
normal
compon
nglycan
bind
sia
gal
galnac
requir
famili
enzym
call
sialyltransferas
st
st
produc
specif
linkag
harduinlep
et
al
paulson
rademach
xia
et
al
instanc
multipl
sia
may
link
togeth
form
polysial
acid
commonli
configur
hildebrandt
et
al
linkag
sia
adjac
sugar
configur
mean
bond
acidlabil
readili
destroy
enzym
known
sialidas
note
solut
unbound
sia
mainli
hydroxyl
posit
axial
ring
equilibrium
minor
aform
vimr
acid
natur
sia
due
carboxyl
c
ioniz
physiolog
ph
pk
give
sia
number
use
featur
highlight
schauer
schauer
fig
structur
differ
sialic
acid
deriv
number
carbon
list
green
aco
refer
acetlyl
two
common
linkag
sia
galactos
form
sialyllactos
sialyllactos
shown
vimr
vimr
et
al
negativelycharg
glycoprotein
mutual
repel
allow
trap
water
molecul
produc
highli
viscou
aqueou
solut
compris
glycocalyx
mani
epitheli
surfac
import
shield
highlight
varki
varki
indic
mammalian
genom
encod
protein
involv
glycosyl
pathway
lehmann
et
al
varki
varki
high
sia
content
mucin
act
lubric
epitheli
surfac
cornea
nasal
mucosa
respiratori
gastrointestin
tract
tissu
contact
environ
mucin
protect
cell
mechan
chemic
damag
gastric
acid
digest
enzym
sia
content
mucin
also
function
decoy
pathogen
bind
sia
respiratori
virus
lehmann
et
al
mucin
produc
goblet
cell
normal
benefit
host
nichol
et
al
howev
certain
diseas
cystic
fibrosi
chang
mucin
composit
allow
increas
bacteri
growth
pathogenesi
xia
et
al
second
main
function
sia
enabl
host
protein
avoid
evad
recognit
bodi
defens
mechan
cap
termin
galactos
sia
mask
recognit
certain
oligosaccharid
asialoglycoprotein
receptor
liver
grewal
et
al
similar
receptor
present
macrophag
sialyl
compound
allow
plasma
macromolecul
longer
period
time
circul
number
glycosyl
site
relat
biolog
function
bank
sun
et
al
convers
halflif
mani
serum
glycoprotein
thyrotropin
erythropoietin
follicl
stimul
hormon
decreas
upon
desialyl
glycosyl
protein
shield
prevent
recognit
limit
host
factor
also
employ
pathogen
influenza
virus
lead
develop
antigen
variat
sun
et
al
final
presenc
sia
glycan
may
also
modul
immun
respons
recognit
siabind
lectin
known
siglec
first
siglec
identifi
sialoadhesin
found
macrophag
oneil
et
al
differ
siglec
molecul
sinc
discov
review
varki
gagneux
mention
previous
sia
undergo
modif
two
common
chang
acetyl
hydroxyl
glycolylneuramin
acid
variant
present
mani
anim
speci
human
former
situat
occur
cao
et
al
schauer
et
al
identif
enzym
sialateoacetyltransferas
candid
recent
identifi
arm
et
al
modif
sia
import
consid
chang
particular
oacetyl
may
effect
enzymat
cleavag
sialidas
schauer
demonstr
posit
acetyl
effect
sialidas
activ
oacetyl
group
c
reduc
cleavag
c
schauer
bacteria
virus
notabl
influenza
c
viru
coronavirus
circumv
protect
mechan
develop
esteras
locat
cytosol
lysozym
although
influenza
c
viru
appear
lack
sialidas
activ
still
abl
agglutin
red
blood
cell
certain
speci
led
find
esteras
combin
haemagglutinin
fusion
protein
form
hef
present
influenza
c
coronavirus
martin
et
al
oacetyl
one
common
modif
sialic
acid
initi
thought
speciesspecif
determin
klein
roussel
tissu
local
variant
investig
use
specif
monoclon
antibodi
argueso
sumiyoshi
bind
influenza
c
viru
recombin
solubl
form
coupl
fc
portion
human
immunoglobulin
chefcd
mandal
et
al
studi
show
oacetyl
sialic
acid
human
appear
local
suprabas
plasma
membran
cell
expos
wet
surfac
cornea
conjunctiva
laryng
vagin
epithelium
variat
degre
oacetyl
ethnic
background
depend
whether
individu
slow
fast
acetyl
apart
sialidas
arthrobact
urefacien
actinomyc
viscosu
lesser
extent
sialidas
newcastl
diseas
viru
sialidas
appar
effect
cleav
termin
sialic
acid
oacetyl
inhibit
sialidas
steric
competit
thu
oacetyl
mucin
protect
action
bacteri
sialidas
oacetly
conspicu
termin
aspect
glycoprotein
long
extracellular
domain
prevent
infect
intact
epithelium
common
modif
addit
oxygen
form
nglycolylneuramin
acid
action
enzym
cytidin
monophosph
nacetylneuramin
hydroxylas
cmah
mani
studi
ajit
varki
colleagu
shown
high
express
enzym
mani
anim
speci
human
lack
cmah
activ
sourc
diet
addit
oxygen
import
sialidas
point
view
mani
bacteri
viral
sialidas
prefer
cleav
configur
davi
et
al
viral
sialidas
newcastl
diseas
viru
fowl
plagu
influenza
virus
also
show
poor
cleavag
molecular
dynam
studi
suggest
conform
chang
induc
extra
oxygen
may
explain
decreas
activ
bacteri
sialidas
use
potenti
therapeut
agent
two
chang
oacetyl
practic
implic
agent
one
abl
break
mucin
barrier
cleav
sialic
acid
surfac
epitheli
cell
case
enzymat
cleavag
enzymat
cleavag
unlik
major
concern
lack
cmah
enzym
human
thu
mucin
exclus
howev
oacetyl
enzymat
cleavag
may
concern
topic
therapi
use
region
bodi
high
degre
oacetyl
nonkeratin
stratifi
squamou
epithelium
present
eye
larynx
addit
recognit
siglec
sia
also
function
receptor
number
respiratori
viral
agent
discov
abil
caus
clump
agglutin
red
blood
cell
vitro
haemagglutin
virus
replic
intracellularli
follow
logic
success
attach
cell
requir
match
receptor
pathogen
often
twostep
process
first
lowaffin
brows
follow
higheraffin
interact
viru
specif
receptor
interact
heland
et
al
extens
list
virus
util
sia
may
infect
respiratori
tract
review
lehmann
colleagu
lehmann
et
al
even
though
influenza
viru
well
character
pathogen
studi
must
note
virus
includ
cytomegaloviru
taylor
cooper
rhinoviru
blomqvist
et
al
mump
urab
rey
leyva
et
al
paramyxovirus
util
sia
suzuki
et
al
paulson
et
al
suggest
sialidas
treatment
may
potenti
use
infect
bacteria
abl
produc
sia
de
novo
synthesi
use
sialyl
precursor
scaveng
anim
host
synthesi
sia
bacteria
limit
mostli
pathogen
speci
incorpor
sia
surfac
structur
capsular
polysial
acid
found
neisseria
meningitidi
escherichia
coli
plumbridg
vimr
sia
incorpor
synthes
use
growth
factor
sourc
carbon
kim
et
al
stafford
et
al
vimr
et
al
bacteria
util
sia
includ
neisseria
haemophilu
bacteroid
fusobacteria
streptococci
achiev
scaveng
effect
bacterium
first
requir
sialidas
remov
sia
host
environ
enzym
catabol
follow
uptak
bacterium
util
latter
two
step
elucid
excel
review
process
avail
vimr
et
al
anoth
outcom
sialyl
bacteri
surfac
similar
mention
virus
abl
avoid
recognit
host
defens
mechan
sialyl
result
recognit
self
rather
foreign
microorgan
sialidas
activ
sever
bacteria
streptococcu
pneumonia
produc
one
sialidas
nana
nanb
nanc
gut
et
al
sialidas
pneumonia
may
expos
host
receptor
desialyl
host
glycoprotein
lactoferrin
immunoglobulin
clear
bacteria
may
also
lead
desialyl
lipopolysaccharid
bacteria
n
meningitidi
haemophilu
influenza
give
pneumococcu
competit
growth
advantag
pettigrew
et
al
nana
cell
surfaceanchor
function
adher
may
also
provid
carbon
sourc
bacterium
similar
mani
bacteri
sialidas
nanb
secret
extracellular
enzym
implic
sever
pneumococc
infect
manco
et
al
desialyl
may
also
involv
respiratori
epithelium
previou
concern
whether
desialyl
epithelium
bacteri
viral
sialidas
may
lead
increas
bacteri
adher
superinfect
well
recogn
patient
influenza
suscept
secondari
bacteri
infect
van
der
sluij
et
al
high
mortal
influenza
pandem
attribut
secondari
infect
brundag
shank
sialidas
use
prophylact
therapeut
strategi
therefor
concern
may
lead
increas
bacteri
adher
secondari
bacteri
pneumonia
zhang
realiti
increas
adher
due
epitheli
necrosi
exposur
basement
membran
result
viralinduc
cell
death
plotkowski
et
al
rather
surfaceinduc
desialyl
associ
epitheli
cell
death
nichol
et
al
although
sequenc
homolog
among
differ
bacteri
sialidas
less
uniqu
motif
conserv
region
sialidas
domain
catalyt
domain
clostridium
perfringen
sialidas
determin
nmr
share
key
featur
bacteri
sialidas
newstead
et
al
includ
cluster
three
arginin
interact
carboxyl
acidbas
catabol
asp
hydrophob
pocket
accommod
nacetyl
group
three
water
molecul
involv
bridg
side
chain
ligand
despit
mani
overal
similar
structur
bacteri
sialidas
display
prefer
differ
linkag
manner
clearli
relat
bacteri
speci
rang
divers
bacteri
sialidas
specif
initi
studi
character
schauer
earli
corfield
et
al
corfield
et
al
instanc
bacteroid
fragili
prefer
linkag
b
fragili
appear
quit
flexibl
prefer
even
possibl
bacteria
differ
specif
nana
pneumonia
cleav
linkag
extracellular
nanb
prefer
substrat
linkag
broad
rang
specif
attribut
number
mechan
includ
configur
activ
site
role
water
molecul
nucleophil
crystal
structur
nanb
use
demonstr
cleavag
specif
propos
addit
rim
residu
arginin
triad
may
allow
configur
bind
gut
et
al
sia
primari
recognit
site
mani
viral
respiratori
pathogen
would
seem
appropri
bacteri
sialidas
could
use
inhibitori
agent
cleav
sia
surfac
receptor
thu
block
bind
achiev
would
requir
number
properti
first
effect
sialidas
would
need
broad
catalyt
activ
agent
influenza
viru
bind
depend
linkag
sia
galactos
first
evid
influenza
demonstr
roger
paulson
desialyl
red
blood
cell
resialyl
use
specif
sialyltransferas
either
link
avian
equin
virus
agglutin
former
human
swine
virus
agglutin
latter
studi
paradigm
emerg
avian
virus
primarili
bind
human
swine
virus
bind
wilk
et
al
duck
waterfowl
contain
mainli
termin
sia
intestin
would
littl
select
pressur
avian
virus
acquir
bind
crossspeci
transmiss
would
requir
number
mutat
ferret
exampl
nine
passag
high
inoculum
requir
adapt
viru
avian
configur
sorrel
et
al
recent
studi
usa
imai
et
al
netherland
herfst
et
al
shown
undergo
natur
purifi
neg
select
rather
diversifi
posit
select
multipl
introduc
mutat
requir
avian
virus
develop
greater
affin
receptor
replic
ferret
upper
respiratori
tract
lead
transmiss
lectin
bind
studi
shown
nlink
sialic
acid
distribut
throughout
upper
lower
respiratori
tract
human
increas
distribut
olink
sialic
acid
lower
respiratori
tract
nichol
et
al
sialidas
use
prevent
influenza
human
would
therefor
one
cleav
type
linkag
present
upper
lower
airway
use
therapi
respiratori
tract
infect
sialidas
also
effect
topic
inhal
agent
mention
previous
one
properti
sia
protect
self
glycoprotein
recogn
foreign
sialidas
administ
system
could
lead
widespread
desialyl
glycoprotein
suppress
siglec
pathway
instanc
sinc
erythrocyt
remov
circul
desialyl
propos
system
sialidas
treatment
might
result
widespread
erythrophagocytosi
biondi
et
al
bratosin
et
al
furthermor
mani
viral
respiratori
pathogen
infect
upper
lower
respiratori
tract
includ
alveoli
sialidas
would
need
aerosol
nebul
form
allow
even
distribut
throughout
airway
final
mechan
retent
extracellular
environ
avoid
rapid
catabol
would
advantag
effect
pharmacokinet
sialidas
demonstr
inhibit
influenza
viru
infect
number
vitro
experi
even
sia
proven
receptor
influenza
virus
observ
sia
enzymat
remov
cell
surfac
cell
less
suscept
infect
gottschalk
et
al
work
use
bacteri
sialidas
cell
line
show
reduct
influenza
viru
infect
bergelson
et
al
griffin
et
al
sialidas
micromonospora
viridifacien
use
destroy
influenza
receptor
air
laver
find
translat
practic
approach
two
report
use
sialidas
success
block
respiratori
viru
infect
first
approach
use
sialidas
vibrio
cholera
treat
influenza
parainfluenza
viru
three
infect
thompson
et
al
second
use
bacteri
sialidas
coupl
amphiregulin
test
antiinfluenza
activ
malakhov
et
al
second
compound
call
use
sialidas
viscosu
coupl
sialidas
amphiregulin
allow
bind
respiratori
epithelium
thu
prolong
durat
drug
effect
viscosu
one
first
bacteria
colon
surfac
teeth
abundantli
present
patient
gingiv
haffaje
et
al
implic
immunopathogen
role
periodont
diseas
mahanonda
et
al
propos
continu
swallow
bacterium
lead
lowgrad
immunolog
respons
induct
oral
bacteri
toler
sosroseno
et
al
sialidas
viscosu
chosen
three
reason
like
mani
bacteri
sialidas
effect
cleav
mani
type
sia
high
specif
activ
normal
commens
oral
caviti
would
natur
antibodi
result
oral
toler
sialidas
viscosu
studi
teufel
colleagu
found
primarili
secret
cellbound
teufel
et
al
though
higher
hydrolysi
rate
linkag
also
effect
cleav
linkag
also
abl
cleav
gangliosid
uncommon
properti
among
bacteri
sialidas
acetyl
sia
still
allow
cleavag
attack
amphiregulin
acid
glycoprotein
discov
shoyab
et
al
review
busser
et
al
one
featur
epidermalgrowth
factor
egf
like
domain
homolog
member
egflik
growth
factor
famili
mean
bind
egf
receptor
present
epitheli
cell
unlik
mani
member
egf
famili
amphiregulin
bind
lead
egfr
degrad
recycl
receptor
continu
accumul
surfac
willmarth
et
al
end
protein
heparinand
glycosaminoglycanbind
domain
involv
inhibit
transform
glycoprotein
henc
name
amphiregulin
case
sialidas
combin
gagbind
portion
human
ar
bind
negativelycharg
glycosaminoglycan
surfac
airway
epitheli
cell
cation
ctermin
amphiregulin
tag
anchor
respiratori
epithelium
improv
potenc
net
effect
combin
sialidas
amphiregulin
mean
sialidas
target
epitheli
cell
line
respiratori
tract
without
activ
egfr
pathway
test
ferret
human
airway
epithelium
model
shown
activ
wide
rang
influenza
b
virus
malakhov
et
al
compar
sialidas
higher
activ
stabl
wide
rang
ph
valu
would
present
respiratori
tract
singl
treatment
effect
desialyl
mdck
cell
day
recoveri
day
howev
later
treatment
regimen
adopt
daili
dose
schedul
amphiregulin
attach
increas
potenc
malakhov
et
al
appreci
cell
toxic
number
establish
cell
line
endogen
product
interferon
tnfa
seen
indic
amphiregulin
tag
detriment
host
cell
inhal
toxic
evalu
spraguedawley
rat
repeat
daili
exposur
inhal
day
achiev
dose
mgkgday
well
toler
clinic
sign
affect
treatment
minim
signific
decreas
red
blood
cell
haematocrit
hemoglobin
identifi
togeth
increas
reticulocyt
count
keep
mild
anemia
system
absorpt
respiratori
tract
estim
larson
et
al
studi
also
increas
alkalin
phosphatas
alp
liver
attribut
diminish
clearanc
owe
competit
asialoglycoprotein
receptor
rise
alp
associ
evid
hepatotox
thought
desialyl
serum
protein
may
lead
satur
asialoglycoprotein
receptor
asgr
liver
spleen
reduc
clearanc
certain
glycoprotein
includ
alp
studi
done
human
airway
epitheli
cell
studi
desialyl
effect
seen
min
presenc
mucu
interfer
desialyl
fig
similar
chang
also
seen
freshli
isol
human
bronchial
ex
vivo
cultur
hae
model
resialyl
achiev
day
wherea
without
amphiregulin
tag
resialyl
much
faster
h
postexposur
regimen
also
produc
reduct
viral
titr
infect
thu
demonstr
could
therapeut
well
prophylact
role
also
demonstr
anim
model
treatment
h
postinfect
reduc
mortal
viral
load
mice
infect
addit
studi
done
lung
exvivo
infect
use
virus
trianabaltz
et
al
show
similar
reduct
viral
infect
without
toxic
formul
drypowd
microparticl
diamet
rang
lm
use
proprietari
temperaturecontrol
organ
solvent
assist
precipit
tosap
technolog
drug
deposit
test
use
cast
human
airway
expect
smaller
particl
lm
associ
increas
deposit
deep
lung
higher
system
exposur
compar
lm
particl
use
airway
model
relenza
deposit
distal
bronchi
lung
data
compani
file
phase
trial
lm
size
use
current
phase
clinic
studi
compar
lm
lm
particl
singl
phase
ii
studi
complet
compris
particip
pcrconfirm
influenza
inclus
criteria
male
femal
particip
age
gave
inform
consent
gener
good
health
febril
oral
temperatur
report
temperatur
felt
feverish
past
h
one
respiratori
cough
sore
throat
nasal
symptom
constitut
symptom
headach
myalgia
sweatchil
prostrat
two
treatment
arm
one
singl
dose
mg
second
use
mgday
day
mean
age
patient
multipledos
arm
year
singledos
arm
year
placebo
arm
year
slight
femal
predomin
treatment
arm
thirtyseven
percent
particip
confirm
infect
influenza
b
season
mutat
identifi
would
confirm
oseltamivirresist
phenotyp
subtyp
influenza
virus
trial
conduct
mani
geograph
area
thu
allow
evalu
broad
rang
commonli
circul
influenza
virus
studi
demonstr
signific
reduct
viral
load
day
day
dose
group
significantli
shorter
time
sustain
decreas
viral
shed
group
compar
placebo
group
day
dose
schedul
effect
singleday
dose
regimen
chang
flulik
symptom
seen
control
treatment
group
howev
studi
lack
statist
power
design
assess
clinic
differ
among
treatment
group
low
incid
seriou
advers
event
mild
increas
serum
alp
possibl
desialylationmedi
effect
appear
report
increas
secondari
bacteri
pneumonia
number
potenti
concern
sialidas
therapi
includ
system
dissemin
drug
develop
antibodi
role
secondari
bacteri
infect
mention
earlier
viscosu
chosen
natur
commens
oral
caviti
report
chang
immun
exposur
mild
increas
alp
seen
phase
ii
studi
may
due
system
desialyl
chang
hematolog
paramet
identifi
mention
previous
patient
influenza
increas
bacteri
infect
pneumococcu
concern
may
found
treatment
zhang
interact
influenza
viru
infect
secondari
pneumonia
complex
one
investig
mcculler
other
grijalva
griffin
iverson
et
al
karlstrom
et
al
sinc
pandem
associ
increas
bacteri
infect
follow
influenza
infect
recent
pandem
associ
increas
invas
pneumococc
infect
nelson
et
al
suggest
pneumococc
vaccin
includ
vaccin
strategi
futur
pandem
inde
vaccin
strategi
use
pneumococc
vaccin
reduc
incid
influenzaassoci
pneumonia
howev
link
influenza
pneumococc
infect
complic
find
pneumococc
serotyp
associ
secondari
pneumonia
influenza
viru
infect
may
select
favor
growth
particular
serotyp
mcculler
et
al
propos
desialyl
produc
viral
neuraminidas
expos
receptor
allow
increas
bind
pneumococci
follow
invas
point
previous
clear
distinct
need
made
desialyl
viral
infect
induc
topic
therapi
nichol
et
al
therefor
import
studi
whether
sialidas
therapi
lead
increas
risk
secondari
pneumonia
studi
hedlund
colleagu
use
show
contrast
expect
desialyl
appear
protect
mice
secondari
bacteri
colon
also
studi
previous
cite
evid
increas
adher
pneumococci
desialyl
tracheal
epitheli
specimen
nichol
et
al
contrast
chang
induc
influenza
viru
infect
topic
desialyl
explain
differ
patholog
influenza
viru
infect
epitheli
surfac
caus
necrosi
desialyl
chang
induc
bacteri
sialidas
consist
desialyl
viru
infect
acut
epitheli
denud
exposur
basement
membran
allow
adher
pneumonia
sialidas
treatment
alon
cell
cytotox
epitheli
loss
increas
adher
pneumococi
detail
earlier
phase
ii
clinic
studi
document
increas
pneumococc
infect
even
though
influenza
virus
one
lead
pathogen
caus
acut
respiratori
ill
infect
parainfluenza
viru
make
signific
proport
caus
agent
isol
ill
especi
pediatr
popul
weigl
et
al
although
parainfluenza
virus
typic
caus
bronchiti
bronchiol
increasingli
recogn
agent
lower
respiratori
tract
diseas
similar
clinic
present
infect
respiratori
virus
parainfluenza
virus
increas
concern
pediatr
immunocompromis
popul
may
caus
sever
pulmonari
diseas
resembl
influenza
virus
use
sia
receptor
bind
differ
among
strain
villar
barroso
use
sialyl
microarray
recent
demonstr
narrowest
specif
bind
stronger
bind
methyl
deriv
contrast
show
broader
rang
bind
deriv
show
similar
rang
bind
much
lower
magnitud
three
strain
preferenti
bound
glycan
rather
linkag
song
et
al
mechan
bind
releas
piv
differ
influenza
virus
differ
replic
pathway
thu
may
amen
standard
antiinfluenza
therapi
thu
although
zanamivir
inhibit
piv
neuraminidas
activ
prevent
releas
viru
cell
moscona
porotto
et
al
parainfluenza
virus
use
bound
sia
attach
infect
virus
could
amen
sialidas
treatment
even
though
studi
util
use
influenza
target
also
use
patient
parainfluenza
experiment
set
treatment
human
parainfluenza
viruspermiss
cell
line
infect
cotton
rat
led
effect
desialyl
reduc
infect
moscona
et
al
also
use
compassion
emerg
basi
immunocompromis
patient
infect
parainfluenza
viru
benefici
effect
first
case
year
old
femal
stem
cell
transplant
recipi
develop
nasal
congest
cough
follow
clinic
radiolog
featur
viral
bronchiol
worsen
respiratori
function
receiv
three
daili
inhal
administr
use
dri
powder
inhal
show
improv
clinic
radiolog
pulmonari
function
paramet
treatment
infect
confirm
reduct
viral
load
treatment
anoth
report
two
immunocompromis
lung
stem
cell
transplant
recipi
develop
infect
success
treat
develop
lower
respiratori
tract
diseas
case
day
treatment
improv
clinic
symptom
respiratori
function
though
chang
quantit
viral
load
match
clinic
find
guzmansuarez
et
al
howev
recent
case
treatment
pneumonia
lung
transplant
patient
associ
clinic
improv
reduct
viral
load
drozd
et
al
novel
bacteri
sialidas
develop
past
six
year
vitro
test
phase
ii
studi
influenza
viru
infect
agent
show
promis
repertoir
antivir
influenza
also
show
potenti
benefit
respiratori
virus
use
sia
receptor
sever
parainfluenza
viru
infect
